Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21088489 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HSD17B10EPHX1ADH1BADH1A | |
| SCHEMBL23944315 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HSD17B10EPHX1ADH1BADH1A | |
| SCHEMBL999820 | 0.91 | ALDH1A1 (0.53) | ALDH1A1HSD17B10EPHX1ADH1BADH1A | |
| SCHEMBL1000295 | 0.91 | ALDH1A1 (0.61) | ALDH1A1HSD17B10EPHX1ADH1BADH1A | |
| SCHEMBL1002568 | 0.91 | ALDH1A1 (0.61) | ALDH1A1HSD17B10EPHX1ADH1BADH1A | |
| SCHEMBL999821 | 0.91 | ALDH1A1 (0.53) | ALDH1A1HSD17B10EPHX1ADH1BADH1A | |
| SCHEMBL998954 | 0.88 | ALDH1A1 (0.67) | ALDH1A1HSD17B10EPHX1ADH1BADH1A | |
| SCHEMBL998767 | 0.88 | ALDH1A1 (0.67) | ALDH1A1HSD17B10EPHX1ADH1BADH1A | |
| SCHEMBL998765 | 0.88 | ALDH1A1 (0.67) | ALDH1A1HSD17B10EPHX1ADH1BADH1A | |
| SCHEMBL689552 | 0.88 | ALDH1A1 (0.67) | ALDH1A1HSD17B10EPHX1ADH1BADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230231270-A1 | Separator and Application Thereof | MICROCOSM TECHNOLOGY CO., LTD. (TW) | 2023-07-20 | — | — | US | disclosed |
| US-20230231270-A1 | Separator and Application Thereof | MICROCOSM TECHNOLOGY CO., LTD. (TW) | 2023-07-20 | — | — | US | disclosed |
| EP-4213290-A2 | SEPARATOR AND APPLICATION THEREOF | Microcosm Technology Co., Ltd. (TW) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023129464-A1 | POLYMER COMPOSITIONS HAVING DENSIFICATION ACCELERATORS AND ROTATIONAL MOLDING PROCESSES FOR MAKING HOLLOW ARTICLES THEREFROM | CYTEC INDUSTRIES INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| EP-2864310-B1 | STABILIZER COMPOSITIONS CONTAINING SUBSTITUTED CHROMAN COMPOUNDS AND METHODS OF USE | CYTEC TECH CORP (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-2545148-B1 | TITANIUM AND MOLYBDENUM COMPOUNDS AND COMPLEXES AS ADDITIVES IN LUBRICANTS | LUBRIZOL CORP (US) | 2019-08-14 | — | — | EP | disclosed |
| US-9751880-B2 | Electrophotographic photosensitive member, process cartridge, electrophotographic apparatus, and imide compound | CANON KABUSHIKI KAISHA (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9751880-B2 | Electrophotographic photosensitive member, process cartridge, electrophotographic apparatus, and imide compound | CANON KABUSHIKI KAISHA (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20160251483-A1 | Reactive Functional Siloxane Compositions | MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) | 2016-09-01 | — | — | US | disclosed |
| US-20160115163-A1 | ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, ELECTROPHOTOGRAPHIC APPARATUS, AND IMIDE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2016-04-28 | — | — | US | disclosed |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2007-03-08 | — | — | US | disclosed |
| EP-1723128-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-11-22 | — | — | EP | disclosed |
| US-20060241300-A1 | Phosphazenium salt mixtures containing hexakis(amino)diphosphazenium, tetrakis(amino)-phosphonium and polyaminophosphazenium salts | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2006-10-26 | — | — | US | disclosed |
| EP-1597220-A2 | PHOSPHAZENIUM SALT MIXTURES CONTAINING HEXAKIS(AMINO)DIPHOSPHAZENIUM, TETRAKIS(AMINO)-PHOSPHONIUM AND POLYAMINOPHOSPAZENIUM SALTS | Clariant GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005066145-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-07-21 | — | — | WO | disclosed |
| WO-2004074296-A2 | PHOSPHAZENIUM SALT MIXTURES CONTAINING HEXAKIS(AMINO)DIPHOSPHAZENIUM, TETRAKIS(AMINO)-PHOSPHONIUM AND POLYAMINOPHOSPAZENIUM SALTS | CLARIANT GMBH (DE) | 2004-09-02 | — | — | WO | disclosed |
| US-6143917-A | FROM A DIARYL CARBONATE AND AN AMINE COMPOUND HAVING AT LEAST ONE HYDROGEN ATOM LOCATED AT AN N-POSITION UNDER MODERATE CONDITIONS AT A HIGH REACTION RATE WITH A HIGH SELECTIVITY AND WITH A HIGH YIELD | UBE INDUSTRIES, LTD. (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0902014-A1 | PROCESS FOR PRODUCING ARYL CARBAMATES | UBE INDUSTRIES LIMITED (JP) | 1999-03-17 | — | — | EP | disclosed |
| US-4459424-A | SECONDARY AMINE, CARBON DISULFIDE, METAL CONTAINING CATALYST | AKZONA INCORPORATED (US) | 1984-07-10 | — | — | US | disclosed |
| US-3960886-A | Substituted N-arylanilines | STERLING DRUG INC. (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241300-A1 | Phosphazenium salt mixtures containing hexakis(amino)diphosphazenium, tetrakis(amino)-phosphonium and polyaminophosphazenium salts | ANXA3, AP3S1, INPPL1 | ALDH1A1 4043/4885HSD17B10 3554/4885EPHX1 2843/4885 |
| US-20160115163-A1 | ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, ELECTROPHOTOGRAPHIC APPARATUS, AND IMIDE COMPOUND | PPIE, PPIG, PPIA | ALDH1A1 742/4885HSD17B10 2264/4885EPHX1 122/4885 |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | GCK, GCKR, HK1 | ALDH1A1 520/4885HSD17B10 1182/4885EPHX1 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.